- Home
- IRMD vs AQST Comparison
IRMD vs AQST Comparison
Compare IRMD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- AQST
- Stock Information
- Founded
- IRMD 1992
- AQST 2004
- Country
- IRMD United States
- AQST United States
- Employees
- IRMD N/A
- AQST N/A
- Industry
- IRMD Medical/Dental Instruments
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- AQST Health Care
- Exchange
- IRMD Nasdaq
- AQST Nasdaq
- Market Cap
- IRMD 910.4M
- AQST 809.3M
- IPO Year
- IRMD 2014
- AQST 2018
- Fundamental
- Price
- IRMD $89.74
- AQST $5.79
- Analyst Decision
- IRMD Strong Buy
- AQST Strong Buy
- Analyst Count
- IRMD 1
- AQST 7
- Target Price
- IRMD $72.00
- AQST $10.00
- AVG Volume (30 Days)
- IRMD 81.0K
- AQST 2.8M
- Earning Date
- IRMD 11-03-2025
- AQST 11-05-2025
- Dividend Yield
- IRMD 0.75%
- AQST N/A
- EPS Growth
- IRMD 13.00
- AQST N/A
- EPS
- IRMD 1.65
- AQST N/A
- Revenue
- IRMD $80,511,268.00
- AQST $43,397,000.00
- Revenue This Year
- IRMD $12.93
- AQST N/A
- Revenue Next Year
- IRMD $11.26
- AQST $51.39
- P/E Ratio
- IRMD $54.74
- AQST N/A
- Revenue Growth
- IRMD 12.91
- AQST N/A
- 52 Week Low
- IRMD $47.48
- AQST $2.12
- 52 Week High
- IRMD $91.06
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- IRMD 70.99
- AQST 46.55
- Support Level
- IRMD $82.64
- AQST $5.53
- Resistance Level
- IRMD $87.26
- AQST $6.17
- Average True Range (ATR)
- IRMD 2.56
- AQST 0.43
- MACD
- IRMD 0.15
- AQST -0.03
- Stochastic Oscillator
- IRMD 88.00
- AQST 35.98
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.